{"id":"W4395026193","doi":"10.1016/j.clim.2024.109949","title":"7 Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment","year":2024,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Open label; Period (music); Medicine; Extension (predicate logic); Antagonist; Internal medicine; Clinical trial; Computer science; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003963611,0.000325683,0.001949019,0.0001243643,0.00006091091,0.0000191902,0.0001884775,0.0003299013,0.0000547239],"category_scores_gemma":[0.000312128,0.0002163859,0.0003041913,0.0001641603,0.0003790563,0.000116831,0.00008367087,0.0001220798,0.000002644465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001503728,"about_ca_system_score_gemma":0.0003730748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003579323,"about_ca_topic_score_gemma":0.00001602112,"domain_scores_codex":[0.9968008,0.0001631029,0.001834239,0.0006967884,0.0001924585,0.0003126179],"domain_scores_gemma":[0.997252,0.001033858,0.000584486,0.0006953631,0.0003129398,0.0001213191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6813646,0.0480592,0.001215183,0.0001283208,0.002451496,0.0001797369,0.0007481265,0.000001893163,0.009989007,0.00003695148,0.00009443232,0.255731],"study_design_scores_gemma":[0.4867977,0.479723,0.002880646,0.0007349167,0.002005307,0.00004332426,0.0003353218,0.0008618717,0.02340528,0.00007367064,0.0028936,0.0002452965],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993326,0.001327329,0.00008080938,0.0001920308,0.0009609223,0.002871228,0.001162216,0.00003517593,0.00004426398],"genre_scores_gemma":[0.9927094,0.0003172195,0.004361047,0.00001438402,0.000157541,0.0001167219,0.001846396,0.00005451451,0.0004227905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4316638,"threshold_uncertainty_score":0.8823959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08793805410892636,"score_gpt":0.4111665087270736,"score_spread":0.3232284546181472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}